Intimal sarcoma of the inferior vena cava with extension to the right atrium, bilateral renal vasculature, and bilateral venae iliaca communis, accompanied by severe thrombocytopenia

AbstractA 66 ‐year‐old Asian female diagnosed with an occupied mass of the inferior vena cava (IVC) case with extension to the right atrium, bilateral renal vasculature, and venae iliaca communis, which caused severe thrombocytopenia and severe liver and kidney dysfunction. The postoperative pathological dia gnosis was high‐grade undifferentiated intimal sarcoma. There have been less than 10 cases of venous undifferentiated intimal sarcomas reported in the literature, three of which occurred in the IVC. Unfortunately, the patient died of multiple organ failure in the intensive care unit postoperativel y.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: CASE REPORT Source Type: research

Related Links:

Primary effusion lymphoma (PEL) is an aggressive HIV-associated lymphoma with a relatively poor prognosis in the era of effective HIV therapy. Kaposi sarcoma herpesvirus (KSHV) is the etiologic agent, and ~80% of tumors are coinfected with Epstein-Barr virus (EBV). A better understanding of how KSHV-related immune dysregulation contributes to the natural history of PEL will improve outcomes. Twenty patients with PEL diagnosed between 2000 and 2013, including 19 treated with modified infusional etoposide, vincristine, and doxorubicin with cyclophosphamide and prednisone (EPOCH), were identified. We compared their clinical, ...
Source: Blood - Category: Hematology Authors: Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Primary cardiac sarcomas are exceedingly rare, and they commonly result in nonspecific constitutional symptoms such as shortness of breath, weight loss, and anaemia-related fatigue and malaise. However, thromb...
Source: Journal of Cardiothoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Case report Source Type: research
Authors: Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S Abstract Histone deacetylase inhibitors (HDACi) can reverse chemoresistance, enhance chemotherapy-induced cytotoxicity, and reduce sarcoma proliferation in cell lines and animal models. We sought to determine the safety and toxicity of mocetinostat and its ability to reverse chemoresistance when administered with gemcitabine in patients with metastatic leiomyosarcoma resistant to prior gemcitabine-containing therapy. Participants with metastatic leiomyosarcoma received mocetinostat orally, 70 m...
Source: Sarcoma - Category: Cancer & Oncology Tags: Sarcoma Source Type: research
Castleman disease (CD) describes a group of heterogeneous diseases defined by shared lymph node histopathology, including atrophic or hyperplastic germinal centers, prominent follicular dendritic cells, hypervascularization, polyclonal lymphoproliferation, and/or polytypic plasmacytosis. Unicentric CD (UCD) involves a solitary enlarged lymph node that displays CD histopathology, and patients rarely experience systemic symptoms. In contrast, multicentric CD (MCD) involves multiple regions of enlarged lymph nodes, systemic inflammation, cytopenias, and vital organ dysfunction due to a cytokine storm often including interleuk...
Source: Blood - Category: Hematology Authors: Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I Source Type: research
Conclusions: Overall, lurbinectedin was safe and tolerated using the schedules and dose levels tested. While no sustained remissions were observed, single-agent lurbinectedin was transiently leukemia suppressive for some patients.DisclosuresRodríguez: PharmaMar: Employment. Ravandi: Bristol-Myers Squibb: Research Funding; Jazz: Honoraria; Abbvie: Research Funding; Seattle Genetics: Research Funding; Abbvie: Research Funding; Amgen: Honoraria, Research Funding, Speakers Bureau; Orsenix: Honoraria; Seattle Genetics: Research Funding; Astellas Pharmaceuticals: Consultancy, Honoraria; Sunesis: Honoraria; Orsenix: Honora...
Source: Blood - Category: Hematology Authors: Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II Source Type: research
Objective: To investigate the clinical features of 2nd hematological malignancies post to the initial cancer treatment.METHODS: A retrospective study was performed to analyze the available clinical data of 116 patients diagnosed with 2nd hematologic malignancies after treatment of various malignant tumors from June 1998 to June 2018 at Sun Yat-sen University cancer center.RESULTS: The characteristics of the 116 patients diagnosed with 2nd hematological cancer post to initial cancer treatment were indicated as following: 62 males and 54 females. The primary tumor category was grouped as (according to ICD-10 International Di...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions Source Type: research
CONCLUSION: Tocilizumab is safe in patients with HIV and may have a role in the management of symptoms associated with KSHV-MCD. Incomplete responses to tocilizumab may occur because tocilizumab binds to the gp80 IL-6 receptor and KSHV vIL-6 can bind to the gp130 receptor subunit without the requirement for gp80. The addition of AZT and VGC to tocilizumab also showed clinical benefit.DisclosuresUldrick: Celgene: Research Funding; Celgene: Patents &Royalties: 10,001,483 B2; Merck: Research Funding. Yarchoan: NIH: Patents &Royalties: Patents on IL-12 for KS and cereblon-binding drugs for KSHV diseases. Spouse has pat...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster II Source Type: research
Publication date: Available online 16 October 2018Source: The Veterinary JournalAuthor(s): A.S. Moore, A.E. Frimberger, C.M. ChanAbstractCyclophosphamide is an alkylating agent used as chemotherapy for cats with lymphoma, carcinomas and sarcomas. Clinical and pharmacokinetic studies of cyclophosphamide in normal and tumor-bearing cats have shown minimal toxicity and cyclophosphamide at clinically used dosages rarely requires dosage adjustment or treatment delays. Dose intensity appears important for treatment of most cancers; the aim of this study was to perform a modified dose escalation study of cyclophosphamide to estab...
Source: The Veterinary Journal - Category: Veterinary Research Source Type: research
A 40-year-old man with history of AIDS –Kaposi sarcoma involving retroperitoneal lymph nodes, and end-stage renal disease presented with several weeks of shortness of breath and right sided chest discomfort. Physical exam revealed numerous firm, hyperpigmented papules and nodules of the chest. The patient denied a history of antecedent acne and had no family history of hypertrophic or keloidal scarring. Lab work-up revealed thrombocytopenia. Imaging showed lung nodules and multifocal intrathoracic lymphadenopathy.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Cardiovascular & Thoracic Surgery | Intensive Care | Liver | Sarcomas | Thrombocytopenia | Urology & Nephrology